These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9201793)

  • 21. Prospects for pharmacotherapy of schizophrenia.
    Pickar D
    Lancet; 1995 Mar; 345(8949):557-62. PubMed ID: 7539875
    [No Abstract]   [Full Text] [Related]  

  • 22. Serotonin receptor responsivity in schizophrenia.
    Kahn RS; Davidson M
    Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():47-51. PubMed ID: 7911140
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of mianserin on negative symptoms in schizophrenia.
    Mizuki Y; Kajimura N; Imai T; Suetsugi M; Kai S; Kaneyuki H; Yamada M
    Int Clin Psychopharmacol; 1990 Apr; 5(2):83-95. PubMed ID: 1696292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients.
    Farde L; Nyberg S; Oxenstierna G; Nakashima Y; Halldin C; Ericsson B
    J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):19S-23S. PubMed ID: 7537284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
    Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
    J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
    Markianos M; Hatzimanolis J; Lykouras L
    Psychopharmacology (Berl); 2001 Aug; 157(1):55-9. PubMed ID: 11512043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response.
    Nyberg S; Nakashima Y; Nordström AL; Halldin C; Farde L
    Br J Psychiatry Suppl; 1996 May; (29):40-4. PubMed ID: 8733822
    [No Abstract]   [Full Text] [Related]  

  • 29. Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol.
    Nagamoto HT; Adler LE; McRae KA; Huettl P; Cawthra E; Gerhardt G; Hea R; Griffith J
    Neuropsychobiology; 1999; 39(1):10-7. PubMed ID: 9892854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine.
    Arranz MJ; Collier DA; Munro J; Sham P; Kirov G; Sodhi M; Roberts G; Price J; Kerwin RW
    Neurosci Lett; 1996 Oct; 217(2-3):177-8. PubMed ID: 8916101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clozapine: new research on efficacy and mechanism of action.
    Meltzer HY; Bastani B; Ramirez L; Matsubara S
    Eur Arch Psychiatry Neurol Sci; 1989; 238(5-6):332-9. PubMed ID: 2569975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients.
    Suzuki E; Kanba S; Nibuya M; Adachi S; Sekiya U; Shintani F; Kinoshita N; Yagi G; Asai M
    Biol Psychiatry; 1994 Nov; 36(10):654-61. PubMed ID: 7880934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia.
    Ohmori T; Koyama T; Inoue T; Matsubara S; Yamashita I
    Biol Psychiatry; 1993 May; 33(10):687-93. PubMed ID: 8102551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The D2 receptor: love it and leave it.
    Pickar D
    Mol Psychiatry; 1998 Mar; 3(2):101-2. PubMed ID: 9577830
    [No Abstract]   [Full Text] [Related]  

  • 35. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects.
    Nyberg S; Farde L; Halldin C
    Neuropsychopharmacology; 1997 Jan; 16(1):1-7. PubMed ID: 8981383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol.
    Brown AS; Gewirtz G; Harkavy-Friedman J; Cooper T; Brébion G; Amador XF; Malaspina D; Gorman JM
    Neuropsychopharmacology; 1997 Nov; 17(5):317-25. PubMed ID: 9348547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.
    Meltzer HY
    Psychopharmacology (Berl); 1989; 99 Suppl():S18-27. PubMed ID: 2682729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An atypical compound by any other name is still a.
    Meltzer HY
    Psychopharmacology (Berl); 2000 Jan; 148(1):16-9. PubMed ID: 10663411
    [No Abstract]   [Full Text] [Related]  

  • 39. The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis. An open dose-finding study.
    Castelão JF; Ferreira L; Gelders YG; Heylen SL
    Schizophr Res; 1989; 2(4-5):411-5. PubMed ID: 2484825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
    Gefvert O; Bergström M; Långström B; Lundberg T; Lindström L; Yates R
    Psychopharmacology (Berl); 1998 Jan; 135(2):119-26. PubMed ID: 9497016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.